{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:39:25Z","timestamp":1758634765139},"reference-count":0,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>Several new topical agents have been introduced recently and it can be \nexpected that the treatment of glaucoma will change, depending on how \neffectively these agents control intraocular pressure (IOP). IOP is considered \nthe major risk factor in the development of glaucomatous damage. In order to \nestimate the impact of these new agents on the cost of treating glaucoma, a \nsimulation model was created to estimate the cost of treating patients with a \nrecent diagnosis of primary open-angle glaucoma or ocular hypertension in \ndifferent countries. The Markov model is based on retrospective chart reviews \nin different countries and calculates only cost, not outcome. Results are \npresented for France and the United Kingdom, where current treatment appeared \nto be comparable. Average one-year costs per patient with current treatment \nwere FF2,389 (US $389) and \u00a3380 (US $627), respectively. Costs with the \nnew treatments were lower than with current therapy.<\/jats:p>","DOI":"10.1017\/s0266462399015299","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:36:57Z","timestamp":1027762617000},"page":"207-219","source":"Crossref","is-referenced-by-count":28,"title":["MODELING COST OF TREATMENT WITH NEW TOPICAL TREATMENTS FOR GLAUCOMA"],"prefix":"10.1017","volume":"15","author":[{"given":"Gisela","family":"Kobelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[1999,1,1]]},"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462399015299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T15:21:25Z","timestamp":1557501685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462399015299\/type\/journal_article"}},"subtitle":["Results from France and the United Kingdom"],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["S0266462399015299"],"URL":"https:\/\/doi.org\/10.1017\/s0266462399015299","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}